Drugs / Nelonemdaz
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05041010 | Dec 2021 → Jun 2024 | ischemic stroke | GNT Pharma | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nelonemdaz | “Nelonemdaz (Neu2000) has both selective antagonism against 2B subunit of N-methyl-D-aspartate receptor and antioxidant activity.” PMID 36746385 ↗ Jan 2023 |
| Known as | Neu2000 | “Nelonemdaz (Neu2000) has both selective antagonism against 2B subunit of N-methyl-D-aspartate receptor and antioxidant activity.” PMID 36746385 ↗ Jan 2023 |
| Action | Inhibit | “Nelonemdaz selectively antagonizes the 2B subunit of the N-methyl-d-aspartate glutamate receptor” PMID 39874036 ↗ Jan 2025 |
| Route | Intravenous | “receive intravenous infusions of nelonemdaz twice a day for 5 days” PMID 39874036 ↗ Jan 2025 |